The National Institute for Health and Care Excellence

New machines that keep donor livers alive outside the body could help hundreds waiting for a life-saving transplant

A consultation has begun on draft guidance recommending 4 specialist liver preservation machines for routine NHS use, which could help more of the 600 people in England waiting for a life-saving ...
The National Institute for Health and Care Excellence

Routine NHS access to spinal muscular atrophy treatments offers new hope for patients and families

The decision marks a significant milestone after both medicines were previously made available through managed access agreements while additional evidence on their effectiveness was gathered. SMA is a ...
The National Institute for Health and Care Excellence

Neonatal infection guidance updated to allow home antibiotic treatment for some babies

This means mothers whose babies need antibiotics could leave hospital sooner and complete treatment at home with full clinical support, potentially reducing their hospital stay by up to 2.7 days. All ...
National Institute for Health and Care Excellence

NICE approves Duchenne muscular dystrophy treatment givinostat after commercial deal sealed

Today’s final draft guidance says givinostat (also called Duvyzat and made by ITF Pharma) can be used to treat Duchenne muscular dystrophy (DMD) in people aged 6 and over who are able to walk or stand ...
National Institute for Health and Care Excellence

Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...
National Institute for Health and Care Excellence

Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy

Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
National Institute for Health and Care Excellence

DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations: NICE review

We have moved NG251 to become a 'NICE Review'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The review itself has not changed. See ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact UK.pas@gsk.com ...
National Institute for Health and Care Excellence

Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over

There is a simple discount patient access scheme for efanesoctocog alfa. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over

Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over. Selpercatinib is also ...
National Institute for Health and Care Excellence

Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.
National Institute for Health and Care Excellence

Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment

We have moved Health technology evaluation 20 to become HealthTech guidance 739. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme ...